Dongwha Pharm.Co.,Ltd (000020.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	513.2B	496.4B	464.9B	361.1B	340.4B
Cost of Revenue	298.5B	293.1B	250.6B	170.7B	159.4B
Gross Profit	214.8B	203.3B	214.3B	190.4B	181.0B
Operating Expenses
R&D Expense	32.9B	25.7B	23.6B	21.5B	19.3B
SG&A Expense	113.9B	108.2B	104.6B	143.6B	76.6B
General & Admin Expense	18.2B	23.6B	20.8B	66.0B	10.9B
Selling & Marketing Expense	55.9B	84.6B	83.7B	77.5B	65.7B
Other Expenses	70.2B	70.2B	72.7B	59.8B	55.2B
Total Operating Expenses	196.6B	204.1B	200.8B	165.1B	151.1B
Cost and Expenses	495.1B	496.1B	451.5B	342.3B	310.5B
Operating Income (EBIT)	18.1B	(809.2M)	13.4B	25.3B	29.9B
Non-Operating
Interest Income	(741.5M)	1.2B	1.4B	3.3B	2.4B
Interest Expense	990.2M	4.5B	2.2B	308.0M	370.0M
Net Interest Income	(1.7B)	(3.3B)	(725.7M)	2.9B	2.0B
Other Non-Op Income/Expense	(6.1B)	6.8B	(6.5B)	11.7B	(6.8B)
Non-Operating Income (excl Interest)	(1.4B)	—	4.4B	6.6B	4.2B
EBT (Pre-Tax Income)	12.0B	6.0B	6.9B	37.0B	23.1B
Income Tax Expense	(2.6B)	2.2B	4.8B	8.7B	1.5B
Bottom Line
Net Income	18.1B	8.7B	5.6B	27.4B	20.4B
Earnings from Cont. Ops	14.6B	3.8B	2.1B	28.2B	21.6B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	18.1B	8.7B	5.6B	27.4B	20.4B
Per Share
Basic EPS	₩653	₩313	₩201	₩991	₩736
Diluted EPS	₩653	₩313	₩201	₩991	₩736
Revenue Per Share	₩18,517	₩17,772	₩16,772	₩13,043	₩12,299
Shares
Basic Shares Outstanding	27.7M	27.9M	27.7M	27.7M	27.7M
Diluted Shares Outstanding	27.7M	27.9M	27.7M	27.7M	27.7M
Profitability Metrics
EBITDA	41.6B	21.2B	28.7B	48.7B	38.2B
D&A	22.7B	22.0B	19.7B	13.9B	12.5B
EBIT	18.9B	(809.2M)	9.1B	34.8B	25.7B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026